Table 3 The patient demographical, and laboratory outcomes during the hospital stay

43-year old, male, caucasian , BMI:26 kg/m²

None

Fever, weakness, joint pain, abdominal pain, headache, redness eyes, skin lesions

Self isolation between Apr 13-24, 2021, COVID 19 PCR (-) on Apr 13, 2021

PCR (-) on Jun 7-9, 2021; Antibody test (+) on Jun 10 2021

Thorax CT: Normal; Abdominal CT:Normal; Abdominal ultrasonography: grade 1 hepatosteatos; at initial admission:[ECHO EF:60, ECG; negative T and non-specific ST-T segmental changes (V1-V6 )]At the discharge [ECHO: EF 64% and normal ECG.]

Steroid, IVIG, and LMWH

Disovered completely, and discharged at 14th of the treatment

Multiple blood cultures

N

C-reactive protein( < 5 mg/L)

144*

Urine culture

N

D-dimers ( < 500 µg/L)

2033*

Rectal swab for multi-drug resistant bacteria

N

Ferritin (30-400 µg/L)

3978*

HBV and HCV

N

Lactate dehydrogenase (135-225 U/L)

589*

Leptospira

N

White blood count (4.5-10.5x10^9/L)

11.7*

Borrelia burgdorferi

N

Neutrophil count ( 45-78 %)

85.5*

SARS-CoV-2 (PCR)

N

Lymphocyte count (1.32-3.57x10^9/L)

0.74**

SARS-CoV-2 (Antibody test)

P

Platelet count (150–400x10^9/L)

78**

CMV IgG

P

Creatinine (07-1.2mg/dl)

0.9*

CMV IgM

N

Troponin T(0.004 µg/L<)

0.005*

EBV IgG

N

prokalsitonin(< 0.5 µg/L)

2.35*

EBV IgM

N

AST(<40 U/L)

404*

Weil felix test

N

ALT(<41 U/L)

874*

HIV

N

T.Bilirubine(1.2mg/dl<)

2.06*

Rickettsia conorii

N

Sedimantation(mm)

61*

HAV TOTAL

P

Amilaz(28-100 U/L)

60*

HAV IgM

N

Lipaz(13-60 U/L)

55*

Brucella

N

Protrombin time (11"-16.8")

16.4*

TPHA

N

VDRL-RPR

N